Transcriptomic analysis of a phase 1 trial for intraperitoneal monocytes plus IFNs in ovarian cancer reveals support and recruitment of cell-mediated immunity.

J Immunother CancerSep 7, 2026 (epub)
Clinical ResearchOncology (Medical)

Franklin Ning, Emily San Andres-Montalvan, Thomas J Meyer et al.

✦ AI-curated · Sources linked

In 30 seconds

This phase 1 trial investigated the effects of intraperitoneal autologous monocytes with interferons (AMIGA) in women with recurrent, platinum-resistant ovarian cancer. The study found that long-term responders exhibited an increased cell-mediated immune response, with significant upregulation of CXCL10 and CCL2 mRNA in peripheral blood mononuclear cells and malignant ascites, indicating potential for enhanced T cell recruitment.

Key findings

  • Long-term responders showed increased cell-mediated immune responses compared to non-responders.
  • AMIGA treatment led to upregulation of CXCL10 and CCL2 mRNA in peripheral blood mononuclear cells.
  • In vitro models confirmed increases in CXCL10 and CCL2, affecting T-cell chemotaxis.

Why it matters

Understanding the immune response to AMIGA therapy may help refine treatment strategies for recurrent ovarian cancer, potentially improving patient outcomes through enhanced T cell recruitment and activity.

Source

PubMed · PMID 42705863

Published in J Immunother Cancer. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.